Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 7/20 | 0.56 |
| ▸ | PPARG | P37231 | 2/20 | 0.51 |
| ▸ | PPARD | Q03181 | 2/20 | 0.51 |
| ▸ | PPARA | Q07869 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | G6PD | P11413 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Taxiphyllin SCHEMBL50174 | 1.00 | TYR (0.56) | TYRPPARGPPARDPPARAMAPT | |
| Taxiphyllin SCHEMBL467975 | 1.00 | TYR (0.56) | TYRPPARGPPARDPPARAMAPT | |
| Taxiphyllin SCHEMBL12727838 | 1.00 | TYR (0.56) | TYRPPARGPPARDPPARAMAPT | |
| Prunasin SCHEMBL4925774 | 0.88 | SYNJ2 (0.50) | TYRMAPTKDM4EPOLBGAA | |
| Prunasin SCHEMBL30671478 | 0.88 | SYNJ2 (0.50) | TYRMAPTKDM4EPOLBGAA | |
| Prunasin SCHEMBL16147925 | 0.88 | SYNJ2 (0.50) | TYRMAPTKDM4EPOLBGAA | |
| Prunasin SCHEMBL440675 | 0.88 | SYNJ2 (0.50) | TYRMAPTKDM4EPOLBGAA | |
| Prunasin SCHEMBL377612 | 0.88 | SYNJ2 (0.50) | TYRMAPTKDM4EPOLBGAA | |
| SCHEMBL29649717 | 0.88 | TYR (0.60) | TYRPOLB | |
| SCHEMBL30592415 | 0.85 | TYR (0.47) | TYRPPARGPPARDPPARAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2661266-A2 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | Elcelyx Therapeutics, Inc. (US) | 2013-11-13 | — | — | EP | claimed |
| WO-2012094636-A2 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | ELCELYX THERAPEUTICS, INC. (US) | 2012-07-12 | — | — | WO | claimed |
| US-20240108040-A1 | HIGH INTENSITY SWEETENERS | FIRMENICH INCORPORATED (US) | 2024-04-04 | — | — | US | disclosed |
| US-11758933-B2 | High intensity sweeteners | FIRMENICH INCORPORATED (US) | 2023-09-19 | — | — | US | disclosed |
| EP-3368542-B1 | HIGH INTENSITY SWEETENERS | FIRMENICH INCORPORATED (US) | 2022-06-22 | — | — | EP | disclosed |
| US-11357246-B2 | High intensity sweeteners | FIRMENICH INCORPORATED (US) | 2022-06-14 | — | — | US | disclosed |
| CN-110531001-B | Metabolism marker for distinguishing taxus yunnanensis and taxus mairei and detection method thereof | 杭州师范大学 | 2022-03-08 | — | — | CN | disclosed |
| US-20210227863-A1 | HIGH INTENSITY SWEETENERS | SENOMYX, INC. | 2021-07-29 | — | — | US | disclosed |
| EP-3356356-B1 | COMPOUNDS USEFUL AS MODULATORS OF TRPM8 | FIRMENICH INCORPORATED (US) | 2021-05-26 | — | — | EP | disclosed |
| EP-3763419-A1 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | Anji Pharma (US) LLC (US) | 2021-01-13 | — | — | EP | disclosed |
| CN-111896655-A | Method for analyzing and exploring functional metabolites produced by probiotics in digestive tract | 中国农业大学 | 2020-11-06 | — | — | CN | disclosed |
| CN-1249779-A | Cytochrome P450 monooxygenases | NOVARTIS AG (CH) | 2000-04-05 | — | — | CN | disclosed |
| EP-0970191-A2 | CYTOCHROME P450 MONOOXYGENASES | Novartis AG (CH) | 2000-01-12 | — | — | EP | disclosed |
| WO-1999047653-A1 | SUICIDE GENE THERAPY SYSTEM FOR THE TREATMENT OF BRAIN TUMOURS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 1999-09-23 | — | — | WO | disclosed |
| EP-0943680-A1 | Suicide gene therapy system for the treatment of brain tumours | Boehringer Ingelheim International GmbH (DE) | 1999-09-22 | — | — | EP | disclosed |
| US-5882851-A | DNA MOLECULE CODING FOR A CYTOCHROME P-450 MONOOXYGENASE THAT CATALYZES THE CONVERSION OF AN AMINO ACID TO THE CORRESPONDING N-HYDROXYAMINO ACID AND THE CONVERSION OF SAID N-HYDROXYAMINO ACID TO THE CORRESPONDING OXIME | NOVARTIS FINANCE CORPORATION (US) | 1999-03-16 | — | — | US | disclosed |
| WO-1998040470-A2 | CYTOCHROME P450 MONOOXYGENASES | NOVARTIS AG (CH) | 1998-09-17 | — | — | WO | disclosed |
| EP-0733112-A1 | CYTOCHROME P-450 MONOOXYGENASES | Novartis AG (CH) | 1996-09-25 | — | — | EP | disclosed |
| WO-1995016041-A1 | CYTOCHROME P-450 MONOOXYGENASES | CIBA-GEIGY AG (CH) | 1995-06-15 | — | — | WO | disclosed |
| US-4209539-A | HYDRATION OF TOXIC CYANO GROUPS TO AMIDE | ANVER BIOSCIENCE DESIGN, INC. (US) | 1980-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240108040-A1 | HIGH INTENSITY SWEETENERS | TAS2R40, TAS2R60, TAS1R1 | TYR 984/4885PPARG 217/4885PPARD 282/4885 |
| US-11357246-B2 | High intensity sweeteners | TAS2R40, TAS2R60, TAS1R1 | TYR 984/4885PPARG 217/4885PPARD 282/4885 |
| US-20210227863-A1 | HIGH INTENSITY SWEETENERS | TAS2R40, TAS2R60, TAS1R1 | TYR 984/4885PPARG 217/4885PPARD 282/4885 |
| US-11758933-B2 | High intensity sweeteners | TAS2R40, TAS2R60, TAS1R1 | TYR 984/4885PPARG 217/4885PPARD 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.